“Super” high-frequency subthalamic stimulation for managing refractory dyskinesia in Parkinson’s disease

Q3 Medicine

Annals of Movement Disorders Pub Date : 2022-09-01 DOI:10.4103/AOMD.AOMD_11_22

Chayut Kasemsuk, G. Oyama, F. Sasaki, S. Sekimoto, M. Nuermaimaiti, H. Iwamuro, A. Umemura, N. Hattori

{"title":"“Super” high-frequency subthalamic stimulation for managing refractory dyskinesia in Parkinson’s disease","authors":"Chayut Kasemsuk, G. Oyama, F. Sasaki, S. Sekimoto, M. Nuermaimaiti, H. Iwamuro, A. Umemura, N. Hattori","doi":"10.4103/AOMD.AOMD_11_22","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate and compare the effect of “super” high-frequency (SHF; >130 Hz) stimulation and conventional high-frequency (CHF; 100–130 Hz) stimulation on patients with dyskinesia. Methods: The patients were evaluated using the Abnormal Involuntary Movement Scale (AIMS) with SHF and CHF after levodopa infusion. The secondary outcomes included the Burke–Fahn–Marsden dystonia rating scale and the Unified Parkinson’s Disease Rating Scale part III scores. Result: Six patients were enrolled in this study. The AIMS scores were not significantly different between SHF and CHF (p=0.89, paired t-test). Three out of six patients (50%) had better AIMS scores when SHF was applied, the scores of two patients remained unchanged, and one patient had a score worse than that with CHF. No short-term adverse effects were observed. Conclusion: The results of our pilot study show that SHF is safe and tolerable. We believe that in appropriate cases SHF can be used for managing dyskinesia after conventional methods yield unfavorable results.","PeriodicalId":7973,"journal":{"name":"Annals of Movement Disorders","volume":"5 1","pages":"178 - 182"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Movement Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/AOMD.AOMD_11_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate and compare the effect of “super” high-frequency (SHF; >130 Hz) stimulation and conventional high-frequency (CHF; 100–130 Hz) stimulation on patients with dyskinesia. Methods: The patients were evaluated using the Abnormal Involuntary Movement Scale (AIMS) with SHF and CHF after levodopa infusion. The secondary outcomes included the Burke–Fahn–Marsden dystonia rating scale and the Unified Parkinson’s Disease Rating Scale part III scores. Result: Six patients were enrolled in this study. The AIMS scores were not significantly different between SHF and CHF (p=0.89, paired t-test). Three out of six patients (50%) had better AIMS scores when SHF was applied, the scores of two patients remained unchanged, and one patient had a score worse than that with CHF. No short-term adverse effects were observed. Conclusion: The results of our pilot study show that SHF is safe and tolerable. We believe that in appropriate cases SHF can be used for managing dyskinesia after conventional methods yield unfavorable results.

查看原文本刊更多论文

“超”高频丘脑底刺激治疗帕金森病顽固性运动障碍

目的：评价和比较“超”高频（SHF；>130Hz）刺激和常规高频（CHF；100-130Hz）刺激对运动障碍患者的疗效。方法：应用异常非自愿运动量表（AIMS）对患者输注左旋多巴后SHF和CHF进行评定。次要结果包括Burke–Fahn–Marsden肌张力障碍评定量表和联合帕金森病评定量表第三部分评分。结果：本研究共纳入6例患者。SHF和CHF之间的AIMS评分没有显著差异（p=0.89，配对t检验）。当应用SHF时，六分之三的患者（50%）的AIMS评分更好，两名患者的评分保持不变，一名患者的得分比CHF患者差。未观察到短期不良反应。结论：我们的初步研究结果表明SHF是安全和可耐受的。我们认为，在常规方法产生不利结果后，在适当的情况下，SHF可以用于治疗运动障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊